ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Cardiol Therapeutics Inc

Cardiol Therapeutics Inc (CRDL)

1.97
0.02
(1.03%)
Cerrado 05 Octubre 3:00PM
2.06
0.09
(4.57%)
Fuera de horario: 6:54PM

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
2.06
Postura de Compra
1.93
Postura de Venta
2.04
Volume Operado de la Acción
122,322
1.94 Rango del Día 2.01
0.661 Rango de 52 semanas 3.12
Capitalización de Mercado [m]
Precio Anterior
1.95
Precio de Apertura
1.94
Última hora de negociación
Volumen financiero
US$ 240,577
Precio Promedio Ponderado
1.9668
Volumen promedio (3 m)
302,402
Acciones en circulación
69,881,720
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-6.61
Beneficio por acción (BPA)
-0.4
turnover
-
Beneficio neto
-28.13M

Acerca de Cardiol Therapeutics Inc

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solut... Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. Mostrar más

Sector
Coml Physical, Biologcl Resh
Industria
Coml Physical, Biologcl Resh
Sede
Oakville, Ontario, Can
Fundado
-
Cardiol Therapeutics Inc is listed in the Coml Physical, Biologcl Resh sector of the NASDAQ with ticker CRDL. The last closing price for Cardiol Therapeutics was US$1.95. Over the last year, Cardiol Therapeutics shares have traded in a share price range of US$ 0.661 to US$ 3.12.

Cardiol Therapeutics currently has 69,881,720 shares in issue. The market capitalisation of Cardiol Therapeutics is US$136.27 million. Cardiol Therapeutics has a price to earnings ratio (PE ratio) of -6.61.

CRDL Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.06-2.830188679252.122.1481.88093116931.97280916CS
40.1910.16042780751.872.631.7754285332.19450242CS
120.010.4878048780492.052.631.7753024022.12729579CS
260.1910.16042780751.873.121.553989652.21316019CS
521.2774163.2251469460.78263.120.6613446661.82435811CS
156-1.8111-46.78515150733.87114.960.453010421.84451712CS
260-0.57-21.67300380232.634.960.453217092.0661573CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CHSNChanson International Holding
US$ 11.22
(269.08%)
14.76M
PEVPhoenix Motor Inc
US$ 1.0607
(205.24%)
228.42M
ENTOEntero Therapeutics Inc
US$ 0.60
(72.20%)
10.42M
BENFBeneficient
US$ 1.8914
(58.94%)
108.31M
FORDForward Industries Inc
US$ 5.3254
(52.15%)
18.45M
ADDColor Star Technology Company Ltd
US$ 0.2701
(-39.98%)
14.35M
DUOFangDD Network Group Ltd
US$ 2.53
(-32.89%)
27.74M
ICCTiCoreConnect Inc
US$ 0.4102
(-31.50%)
1.65M
ZENAZenaTech Inc
US$ 3.91
(-29.55%)
212.12k
SPAISafe Pro Group Inc
US$ 1.93
(-25.77%)
238.67k
NVDANVIDIA Corporation
US$ 124.92
(1.68%)
244.46M
PEVPhoenix Motor Inc
US$ 1.0607
(205.24%)
228.42M
SQQQProShares UltraPro Short QQQ
US$ 7.43
(-3.63%)
184.47M
NCNCnoco noco Inc
US$ 0.144
(8.60%)
147.38M
BENFBeneficient
US$ 1.8914
(58.94%)
108.31M

CRDL Discussion

Ver más
williams45 williams45 2 meses hace
Cardiol Therapeutics Inc. ($CRDL) is a clinical-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx™ (cannabidiol), is in clinical development with a 52-week trading range of $0.661 to $3.12.
👍️0
Monksdream Monksdream 2 meses hace
CRDL under $3
👍️0
jobynimble jobynimble 3 meses hace
CRDL grabbed some July19 2.50 calls at a nickel, lotto play, chart looking better…
👍️0
Tiger Money Tiger Money 3 meses hace
Good!
👍️0
Sirpeter Sirpeter 3 meses hace
Higher lows...still bullish
👍️0
Tiger Money Tiger Money 3 meses hace
I like!
👍️0
Sirpeter Sirpeter 3 meses hace
>$4 likely
👍️0
Tiger Money Tiger Money 3 meses hace
Back to $3?
👍️0
Sirpeter Sirpeter 3 meses hace
There's volume...looks like run will continue
👍️0
Sirpeter Sirpeter 3 meses hace
Yeah...we need to keep plenty of rainy day cash in the jar lol
👍️0
Tiger Money Tiger Money 3 meses hace
Tough week, no doubt
👍️0
Sirpeter Sirpeter 3 meses hace
My portfolio is in a depression at the moment...may have to eat dirt ala mode for dinner tonight
👍️0
Tiger Money Tiger Money 3 meses hace
There will not be one until after they submit which wu probably be around $1-$1.50 area
👍️0
Sirpeter Sirpeter 3 meses hace
RGDL too high too fast...will wait on pullback
👍️0
Sirpeter Sirpeter 3 meses hace
Will look at it...watch CDRL go lower now that I text you...I bet I jinxed it lol
🤪 1
Tiger Money Tiger Money 3 meses hace
Nice. $RDGL about to go up big time!
👍️0
Sirpeter Sirpeter 3 meses hace
Morning...there are signs this is stablizing...both my CRDL and WMT calls are green this morning

Im finding more and more playing options
are the way to go if careful
👍️0
Tiger Money Tiger Money 4 meses hace
No doubt
👍️0
Sirpeter Sirpeter 4 meses hace
...all depends which way the wind blows
👍️0
Tiger Money Tiger Money 4 meses hace
It looks excessive but wouldn’t be surprised to see the $1-1.50 range after it run up with $2 being the area it settles in before its first leg up following this downturn
👍️0
Sirpeter Sirpeter 4 meses hace
Im thinking they're diluting because they need money for phase 3 trial...otherwise I dont know why the huge sell off
👍️0
Sirpeter Sirpeter 4 meses hace
1.50 could be bottom but 1.75 more likely
👍️0
Tiger Money Tiger Money 4 meses hace
$1 bid here if my $1.50’s get filled
👍️0
Tiger Money Tiger Money 4 meses hace
Nice
👍️0
Sirpeter Sirpeter 4 meses hace
I got em...bought 10
👍️0
Tiger Money Tiger Money 4 meses hace
Agreed
👍️0
Sirpeter Sirpeter 4 meses hace
Nah...it only allows .05 increments...bidding .15...dont want to bid .20...if doesnt fill will let it go and buy something else...tomorrow is a stock mkt holiday and its summer so a weak mkt is expected
👍️0
Tiger Money Tiger Money 4 meses hace
Gm- u get filled?
👍️0
Sirpeter Sirpeter 4 meses hace
GM... bidding 6/19 2.50 calls @.15
👍️0
Tiger Money Tiger Money 4 meses hace
I’m adding about 500-1k a day for the next couple of weeks
👍️0
Sirpeter Sirpeter 4 meses hace
I added a little today...already have plenty...we will do quite well when thos recovers...surprised this crashed
👍️0
Sirpeter Sirpeter 4 meses hace
The wrecking ball hit my portflio this morning lol...I'm holding...will wait out this dip
👍️0
Tiger Money Tiger Money 4 meses hace
Added this morning and adding more now
👍️0
Sirpeter Sirpeter 4 meses hace
Hey we're way oversold here...please add
👍️0
Sirpeter Sirpeter 4 meses hace
Yeah they have a low float...so quite volatile
👍️0
Sirpeter Sirpeter 4 meses hace
Jump all over this...treat the dip as your friend
🎯 1
jobynimble jobynimble 4 meses hace
CRDL, the old buy-the-rumor, sell-the-news…

Biotechs get big swings, doesn’t mean CRDL won’t work out longer term…
👍️ 1
G-star G-star 4 meses hace
What is happening, why the deep plunge?
👍️0
Mrogers23 Mrogers23 4 meses hace
$CRDL Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

https://finance.yahoo.com/news/cardiol-therapeutics-announces-positive-topline-115800368.html
👍️0
Monksdream Monksdream 4 meses hace
CRDL new 52 week high
👍️0
Sirpeter Sirpeter 4 meses hace
Welcome to the Cardiol Therapeutics hotel...our guests sleep well here
👍️ 1
jobynimble jobynimble 4 meses hace
Cardiol Therapeutics (NASDAQ:CRDL) is a Canadian biotech drug developer focused on developing their novel ultrapure cannabidiol formulation, CardiolRx™, for rare inflammatory heart diseases, specifically recurrent pericarditis and acute myocarditis.

Pericarditis is characterized as inflammation of the pericardium, layers of tissue that surround the heart, that affects about 165,000 people in the U.S. annually and has no first-line FDA-approved treatment. Among those treated for acute pericarditis, 15% to 30% may experience recurrent pericarditis.

Currently, anti-inflammatory drugs such as colchicine are prescribed for pericarditis treatment in cases of chronic or recurrent pericarditis. If the patient with pericarditis disease does not respond to anti-inflammatory medications, corticosteroids such as prednisone are prescribed.

More recently, Kiniksa Pharmaceuticals’ ARCALYST® (rilonacept) became the first and only FDA-approved treatment indicated for the treatment of recurrent pericarditis and the reduction in risk of recurrence in adults and children 12 years and older.

ARCALYST is a weekly subcutaneous injection, whereas CardiolRx™ is an oral drug taken twice daily which is a major advantage as the idea of weekly injections could not be as appealing to patients.

Cardiol Therapeutics’ (NASDAQ:CRDL) pre-clinical models showed that by inhibiting activation of the NLRP3 inflammasome pathway, cannabidiol may help resolve the symptoms of pericarditis.

This approach has already demonstrated incredible potential, as the company was granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol Therapeutics followed this major achievement with completing enrollment in its Phase 2, open-label MAvERIC-Pilot study investigating the tolerance, safety, and effect of CardiolRx™ in patients with recurrent pericarditis. The primary endpoint of the trial is the change in patient-reported pericarditis pain using an 11-point numeric rating scale (NRS) from baseline to week 8 with topline results expected in early June.

Not only that, Cardiol Therapeutics recently presented its concurrent Phase II ARCHER trial design at the annual congress of the Heart Failure Association of the European Society of Cardiology. This demonstrated the high level of interest from the cardiology community in novel approaches to treat acute myocarditis, for which there are currently no therapies approved by European and US regulatory authorities.

The ARCHER trial is expected to enroll 100 patients at pre-eminent cardiovascular research centers in the United States, Canada, France, Brazil, and Israel. Patient recruitment has been accelerating due in large part to the growing global awareness of myocarditis, and ARCHER has already exceeded 85% of target enrollment.

Cardiol Therapeutics (NASDAQ:CRDL) expects that results from the ARCHER trial will assist in furthering its understanding of the therapeutic potential of CardiolRx™ and will complement the more advanced MAvERIC-Pilot Phase II study in patients with recurrent pericarditis.

Just to put the opportunity here in context, Future Market Insights expects that the worldwide pericarditis treatment market is likely to be worth $ 6 billion by 2032. ARCALYST’s sales further reaffirm this considering that the drug’s 2023 net revenue grew 90% year-over-year to $233.1 million.

Several analysts have maintained their positive outlook on the company and have high hopes that the June data will further prove CardiolRx™ efficacy in treating recurrent pericarditis. In fact, Joe Gantoss of Chimera Research Group notes, “I won’t be surprised to see the price breaking out the 3-year high at $4.96 if the recurrent-pericarditis data show a clear success and open the path to move to the next stage with Phase-3 trial,” while analysts at H.C Wainwright & Co. issued a $9 price target for the stock.
👍️ 1
jobynimble jobynimble 4 meses hace
https://www.theglobeandmail.com/investing/markets/markets-news/TheNewswire.com/26745778/surging-biotech-ma-reaffirms-massive-opportunity-in-rare-disease-drug-development/
👍️ 1
TrendTrade2016 TrendTrade2016 4 meses hace
First in first out
👍️0
Sirpeter Sirpeter 4 meses hace
Are you picking your nose on this one? You aren't posting...Am I the only one cleaning up here?
👍️0
Sirpeter Sirpeter 4 meses hace
Ripping!
👍️0
Sirpeter Sirpeter 4 meses hace
Will recover next week
👍️0
Hitman970 Hitman970 4 meses hace
Dip and rip!!!!$$$$
👍️0
Sirpeter Sirpeter 4 meses hace
$4 easy then 5
👍️0
Hitman970 Hitman970 4 meses hace
EPIC CALL!!!$$$
👍️0

Su Consulta Reciente

Delayed Upgrade Clock